Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis
Aging · 2023
DOI: 10.18632/aging.205035 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Aging, 2023. Verfasst von Yan Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, Guangxi, P.R. China. Hauptthemen laut MEDLINE: Immunotherapy, Liver Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, Guangxi, P.R. China.
- Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China.
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China.
Zitieren
APA
Lin, Y., Jiang, W., Su, C. Y., & Pan, X. B. (2023). Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis. Aging. https://doi.org/10.18632/aging.205035
Vancouver
Lin Y, Jiang W, Su CY, Pan XB. Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis. Aging. 2023. doi:10.18632/aging.205035
BibTeX
@article{Lin2023,
author = {Lin, Yan and Jiang, Wei and Su, Cui-Yun and Pan, Xin-Bin},
title = {Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.205035}
}
EUVIMED